PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32878799-2	2020	In this study, we investigated the possible therapeutic effect of vismodegib, a new Shh inhibitor, in a mouse CRPC model.	HhAntag691	66-76	sonic hedgehog	Mus musculus	84-87	
34948011-3	2021	In this study, we determined the effect of a sonic hedgehog inhibitor, vismodegib, on the development of CCC.	HhAntag691	71-81	sonic hedgehog	Mus musculus	45-59	
33259959-1	2021	We report a nanoparticle formulation of the SHH-pathway inhibitor vismodegib that improves efficacy for medulloblastoma, while reducing toxicity.	HhAntag691	66-76	sonic hedgehog	Mus musculus	44-47	
33259959-9	2021	Our results show the broad potential for non-targeted nanoparticle formulation to improve systemic brain tumor therapy, and specifically to improve vismodegib therapy for SHH-driven cancers.	HhAntag691	148-158	sonic hedgehog	Mus musculus	171-174	
27143997-8	2016	The interaction between Shh and PI3K/Akt pathways was clarified by specific PI3K inhibitor LY294002 or Shh inhibitor GDC-0449.	HhAntag691	117-125	sonic hedgehog	Mus musculus	24-27	
30645190-6	2019	Treatment with vismodegib, a clinically approved SHH pathway inhibitor, results in a significant reduction in median survival due to premature development of highly proliferative and vascularised undifferentiated tumours.	HhAntag691	15-25	sonic hedgehog	Mus musculus	49-52	
27143997-8	2016	The interaction between Shh and PI3K/Akt pathways was clarified by specific PI3K inhibitor LY294002 or Shh inhibitor GDC-0449.	HhAntag691	117-125	sonic hedgehog	Mus musculus	103-106	
26073903-3	2015	We investigated the treatment effect of mouse HCC with Shh inhibitor GDC-0449.	HhAntag691	69-77	sonic hedgehog	Mus musculus	55-58	
26073903-8	2015	Gene expression of Shh pathway molecules was altered, including upregulated Shh expression and downregulated smoothened expression in tumor fractions after GDC-0449 treatment.	HhAntag691	156-164	sonic hedgehog	Mus musculus	19-22